Baolingbao Biology Co Ltd (SHE:002286) — Market Cap & Net Worth
Market Cap & Net Worth: Baolingbao Biology Co Ltd (002286)
Baolingbao Biology Co Ltd (SHE:002286) has a market capitalization of $572.48 Million (CN¥3.91 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #11840 globally and #3630 in its home market, demonstrating a -0.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Baolingbao Biology Co Ltd's stock price CN¥10.28 by its total outstanding shares 380567380 (380.57 Million). Analyse how efficiently does Baolingbao Biology Co Ltd generate cash to see how efficiently the company converts income to cash.
Baolingbao Biology Co Ltd Market Cap History: 2015 to 2026
Baolingbao Biology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $757.58 Million to $572.48 Million (-2.62% CAGR).
Baolingbao Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Baolingbao Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
Baolingbao Biology Co Ltd's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.70x
Baolingbao Biology Co Ltd's market cap is 3.70 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $757.58 Million | $1.20 Billion | $40.95 Million | 0.63x | 18.50x |
| 2016 | $880.41 Million | $1.38 Billion | $49.34 Million | 0.64x | 17.84x |
| 2017 | $514.13 Million | $1.59 Billion | $49.62 Million | 0.32x | 10.36x |
| 2018 | $291.16 Million | $1.73 Billion | $42.95 Million | 0.17x | 6.78x |
| 2019 | $322.71 Million | $1.81 Billion | $35.23 Million | 0.18x | 9.16x |
| 2020 | $613.34 Million | $2.05 Billion | $49.86 Million | 0.30x | 12.30x |
| 2021 | $731.27 Million | $2.76 Billion | $201.58 Million | 0.26x | 3.63x |
| 2022 | $494.42 Million | $2.71 Billion | $133.17 Million | 0.18x | 3.71x |
| 2023 | $445.98 Million | $2.52 Billion | $53.97 Million | 0.18x | 8.26x |
| 2024 | $410.98 Million | $2.40 Billion | $111.16 Million | 0.17x | 3.70x |
Competitor Companies of 002286 by Market Capitalization
Companies near Baolingbao Biology Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Baolingbao Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Baolingbao Biology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Baolingbao Biology Co Ltd's market cap moved from $757.58 Million to $ 572.48 Million, with a yearly change of -2.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥572.48 Million | +14.99% |
| 2025 | CN¥497.86 Million | +21.14% |
| 2024 | CN¥410.98 Million | -7.85% |
| 2023 | CN¥445.98 Million | -9.80% |
| 2022 | CN¥494.42 Million | -32.39% |
| 2021 | CN¥731.27 Million | +19.23% |
| 2020 | CN¥613.34 Million | +90.06% |
| 2019 | CN¥322.71 Million | +10.83% |
| 2018 | CN¥291.16 Million | -43.37% |
| 2017 | CN¥514.13 Million | -41.60% |
| 2016 | CN¥880.41 Million | +16.21% |
| 2015 | CN¥757.58 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Baolingbao Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $572.48 Million USD |
| MoneyControl | $572.48 Million USD |
| MarketWatch | $572.48 Million USD |
| marketcap.company | $572.48 Million USD |
| Reuters | $572.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and mal… Read more